ClinicalTrials.gg
CompletedNCT07422961WOMEN-EX-ICUpdated Feb 27, 2026

Response to Aerobic Training in Postmenopausal Women With Exercise Intolerance.

An interventional study of Training in Menopause, Physical Activity and Prevention, sponsored by University of Poitiers. Completed at 1 site in France. Open to female participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by University of Poitiers · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Sep 2022, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 368 studies in Motor Activity with a site in France — 77 open to participants now, 89 under way, none of them phase 3. Motor Activity · France.

Enrollment
171st of 270
43 · median 62
Started
2022
with 24 others
No phase
255 of 368
52 open now
Registered
346th of 368
by date

Among the 368 studies in Motor Activity with a site in France, this one is the 171st largest by enrollment of the 270 interventional ones that give a count, is one of 25 that started in 2022, is one of 255 with no phase, and was the 346th registered.

Motor Activity

9,826 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

77 of the 368 studies in Motor Activity with a site in France are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 40 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 368 studies in Motor Activity with a site in France, or all of them as a file.
02

Study summary

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide and represent a major public health challenge, with growing evidence highlighting important sex-related differences in their epidemiology, clinical presentation, and pathophysiology. In particular, menopause is associated with an increased cardiovascular risk, likely due to the decline in sex hormones and related changes in cardiac structure and function, vascular properties, and metabolic regulation. Several studies show that physical activity and, more specifically, aerobic training improves exercise tolerance and quality of life in patients. However, no studies have evaluated the effects of hormonal status, despite numerous studies on healthy subjects highlighting the influence of sex hormones on cardiovascular responses to acute and chronic exercise.

Read the detailed description

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide and represent a major public health challenge. Importantly, growing evidence highlights significant sex-related differences in the epidemiology, clinical presentation, and pathophysiology of cardiovascular diseases. In particular, postmenopause represents a period of life associated with an increased risk of CVD.

Several physiological mechanisms may underlie these sex-related disparities. Differences in cardiac structure and function, vascular properties, and metabolic regulation contribute to distinct cardiovascular health between men and women. Moreover, the transition to menopause and the associated decline in circulating sex hormones are thought to play a key role in cardiovascular remodeling and functional alterations.

For many years, physical activity has been considered a first-line non-pharmacological strategy in the prevention and treatment of cardiovascular diseases. More specifically, aerobic training has been shown to improves exercise tolerance and quality of life in patients. Indeed, sentinel studies highlight an improvement in aerobic power (VO2 peak) linked to peripheral adaptations (increase in the arteriovenous difference in O2 in the muscles used) and not to central adaptations (no changes in systolic and diastolic functions). However, these studies did not assess the effects of hormonal status , whereas numerous studies on healthy subjects have highlighted the influence of sex hormones on cardiovascular responses to acute and chronic exercise.

The aims of this study:

  • Evaluate the effects of 24 aerobic training sessions (over 8-12 weeks) on exercise tolerance in postmenopausal women (peak VO2 and exercise dyspnea using the Borg scale).
  • Second, evaluate the effects of 24 aerobic training sessions key indices of cardiovascular physiology (e.g., arterial stiffness, endothelial dysfunction, and muscle oxygenation).
  • Thirds, to evaluate the effects of the training sessions on the quality-of-life score of postmenopausal women.
03

Conditions studied

  • Menopause
  • Physical Activity
  • Prevention
  • Cardiovascular (CV) Risk

Browse trials for

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women under 70 years of age (absence of menstruation for 12 consecutive months and estradiol \< 20 pg/mL and/or FSH > 40 mIU/mL), presenting with unexplained exertional dyspnea.
  • COVID-19 vaccination.
  • Echocardiographic > 50% and NT-proBNP \< 220 pg/mL.
  • Women in sinus rhythm or with paroxysmal or permanent atrial fibrillation.
  • Women considered physically inactive according to WHO recommendations (150 minutes of moderate-intensity endurance activity per week, or at least 75 minutes of vigorous-intensity endurance activity, or an equivalent combination of moderate- and vigorous-intensity activity.

Exclusion criteria

Exclusion Criteria:

  • Women with significant coronary heart disease, severe valvular disease (grade III or IV/IV), significant hypertrophic or hypertensive heart disease (LVH with wall thickness ≥ 13 mm), infiltrative disease (amyloidosis, Fabry disease, etc.), constrictive disease, or significant and/or progressive arrhythmic disease (ventricular arrhythmia).
  • Women with significant obesity ( > 30 kg/m²).
  • Unstable women (systolic blood pressure \< 100 mmHg, resting heart rate > 100 bpm) or women with clinical congestion (cardiac-related lower limb edema, pulmonary crackles).
  • Women with pulmonary function tests indicating significant respiratory disease (/FVC \< 0.7, TLC \< LLN).
  • Women with chronic renal failure with \< 30 mL/min () or on dialysis.
  • Women with anemia ( \< 12 g/dL).
  • Women with uncontrolled hypo- or hyperthyroidism (abnormal TSH).
  • Women who have undergone left breast augmentation (implant).
  • Women under legal guardianship or conservatorship.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Training

    24 sessions of adapted physical activity at moderate intensity (aerobic exercise)

    Other: Training

  • No intervention
    Control

    Maintaining lifestyle habits

Interventions

  • OtherTraining

    24 sessions of adapted physical activity at moderate intensity (aerobic exercise)

06

What researchers measure

Primary outcomes

  1. Cardiorespiratory fitness

    Maximal cardiopulmonary exercise test (VO2 peak) on a cycloergometer using an incremental protocol, supervised by a cardiologist. The test started at 30 watts, increasing by 15 watts per minute until maximum capacity was reached.

    Time frame: At Visit 1 and Visit 3 (30 minutes)

Secondary outcomes

  1. Exercise tolerance

    Modified Borg scale during the cardiorespiratory exercise test (scored 0 to 10, higher score indicates lower exercise tolerance).

    Time frame: At Visit 1 and Visit 3 (30 minutes)

  2. Muscle oxygenation

    Near-infrared spectroscopy is used to measure concentrations of oxygenated and desoxygenated hemoglobin (µmol/L) during the cardiorespiratory exercise test.

    Time frame: At Visit 1 and Visit 3 (30 minutes)

  3. Body composition

    Percentage of body fat and fat-free mass using the Tanita impedance scale.

    Time frame: At Visit 2 and Visit 4 (5 minutes)

  4. Body mass index

    Calculated from total body weight and height (kg/m²).

    Time frame: At Visit 2 and Visit 4 (5 minutes)

  5. Aortic systolic and diastolic blood pressure

    At rest, using the SphygmoCor device, which measures central blood pressure (mmHg).

    Time frame: At Visit 2 and Visit 4 (15 minutes)

  6. Arterial stiffness (pulse wave velocity)

    At rest, using the SphygmoCor device, which calculates carotid-femoral pulse wave velocity (m/s).

    Time frame: At Visit 2 and Visit 4 (15 minutes)

  7. Endothelial function (brachial artery dilation capacity)

    At rest, the flow-mediated dilatation technique is used with high-resolution Doppler ultrasound (CX-50 Philipps).

    Time frame: At Visit 2 and Visit 4 (30 minutes)

  8. Systolic and diastolic blood pressure (ambulatory blood pressure measurement)

    Systolic and diastolic blood pressure profile using the Mobil-O-Graph (mmHg).

    Time frame: After Visit 2 and Visit 4 (during 24 hours)

  9. The Menopause-specific Quality of Life Questionnaire (MENQOL)

    Composed of 29 items rating the impact of self-reported climateric symptoms in four domains (vasomotor, psychosocial, physical, and sexual).

    Time frame: At Visit 2 and Visit 4 (10 minutes)

  10. SF-36 questionnaire

    36-item self-report questionnaire measuring health-related quality of life across eight domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health)

    Time frame: At Visit 2 and Visit 4 (10 minutes)

Other outcomes

  1. Age

    Age, and menopause age (in years)

    Time frame: Baseline

  2. Number of children

    Self-reported

    Time frame: Baseline

  3. Tobacco use

    Current, former, never

    Time frame: Baseline

  4. Comorbidities

    Time frame: Baseline

  5. Medical treatment

    Time frame: Baseline

  6. Physical activity level

    Ricci \& Gagnon Questionnaire - Inclusion criteria

    Time frame: Baseline (5 minutes)

  7. Blood hormone concentrations

    17-beta-estradiol, and follicle-stimulating hormone (ng/L) - Inclusion criteria

    Time frame: Baseline

  8. NTproBNP

    Biomarker of cardiac insufficiency (pg/mL) - Inclusion criteria

    Time frame: Baseline

  9. TSH

    Biomarker of uncontrolled thyroid (MUI/L) - Inclusion criteria

    Time frame: Baseline

  10. Complete Blood Count

    Hemoglobin (g/dL), hematocrit (%) - Inclusion criteria

    Time frame: Baseline

  11. Spirometry

    FEV₁/FVC ratio - Inclusion criteria

    Time frame: At Visit 1 (baseline, 15 minutes)

  12. Stress echocardiography

    A progressive incremental exercise test performed on a supine ergometer, combined with echocardiographic measurements taken before, during, and after exercise in order to detect ischemia, contractile abnormalities, valvular dysfunction. - Inclusion criteria

    Time frame: At Visit 1 (baseline, 30 minutes)

07

Study locations

1 site
  • University of Poitiers - UFR STAPS - Laboratory MOVE
    Poitiers, 86000, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jun 2025, 33 months.

Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's 33 months is above that.

Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 20, 2026
StartActual
Sep 21, 2022
Primary completionActual
Jun 24, 2025
CompletionActual
Jul 7, 2025
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07422961
Lead sponsor
University of Poitiers
Collaborators
Elsan
Responsible party
Laurent Bosquet (Professor, University of Poitiers) — Principal investigator
First posted
Feb 20, 2026
Start date
Sep 21, 2022
Primary completion
Jun 24, 2025
Completion
Jul 7, 2025
Last update
Feb 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion